Delivery Order SPE2DB22D3019-SPE2DB25FK4EF
- Not listed
- The Defense Logistics Agency awarded a $15,567.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of UBRELVY 100 mg tablets (unit dose, 10s). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription migraine treatment, indicating this delivery order supports military or federal...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,146.05 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets in unit-dose packaging (10-count) on August 15, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (100-count unit dose packages) valued at $32,471.79 under a firm fixed-price contract type. The order, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a non-competitive, non-set-aside award to support federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a $3,359.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY (50 mg tablet) with completion scheduled for September 17, 2025. This is a non-set-aside competitive award, with the place of performance located in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $1,375.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment...
- The Defense Logistics Agency awarded a delivery order valued at $3,420.49 to AmerisourceBergen Drug Corp for the supply of UBRELVY (an FDA-approved migraine treatment) in 100 mg tablet form on August 20, 2025, with completion expected by August 21, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK4EFDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,376.11 for UBRELVY 100 mg tablets (16-count unit dose packages) on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 through December 2026. The pharmaceutical product is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, and this delivery order supports the Defense Health Agency and military healthcare systems' pharmaceutical supply needs. AmerisourceBergen Drug Corp, headquartered in Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor. The company's SPE2DX contract vehicle functions as a comprehensive global pharmaceutical support program, enabling the supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The DLA Troop Support is planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards, positioning AmerisourceBergen among the key vendors in this strategic healthcare procurement initiative.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.4k | 9/4/25 |